Content analysis of continuing medical education for cervical cancer screening

Journal of Women's Health

Volumn 19, Issue 4, 2010, Pages 651-657

  Roland, Katherine B ^a   Larkins, Teri L ^a   Benard, Vicki B ^a   Berkowitz, Zahava ^a   Saraiya, Mona ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ARTICLE; CANCER SCREENING; CONTENT ANALYSIS; HEALTH PROMOTION; HUMAN; INTERNET; MEDICAL EDUCATION; MEDICAL LITERATURE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

CURRICULUM; EDUCATION, MEDICAL, CONTINUING; FEMALE; GUIDELINE ADHERENCE; HUMANS; INTERNET; MALE; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; QUALITATIVE RESEARCH; SOFTWARE; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77951790095     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2009.1928     Document Type: Article

References (30)

1. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996;334:1030-1038.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
4. ACOG Practice Bulletin no. 61: Human papillomavirus. Obstet Gynecol 2005;105:905-918.
5. Cox JT. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management. Obstet Gynecol Surv 2006;61(Suppl 1):S15-S25.
6. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103: 619-631.
7. Kulasingam SL, Myers ER, Lawson HW, et al. Costeffectiveness of extending cervical cancer screening intervals among women with prior normal Pap tests. Obstet Gynecol 2006;107:321-328.
8. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41.
9. ACOG Practice Bulletin no. 109: Cervical Cytology Screening. Obstet Gynecol 2009;114:1409-1420.
10. Waller J, Marlow LA, Wardle J. Anticipated shame and worry following an abnormal Pap test result: The impact of information about HPV. Prev Med 2009;48:415-419.
11. Marinopoulos SS, Dorman T, Ratanawongsa N, et al. Effectiveness of continuing medical education. Evid Rep Technol Assess 2007;149:1-69.
12. Schuster RJ, Terwoord NA, Tasosa J. Changing physician practice behavior to measure and improve clinical outcomes. Am J Med Qual 2006;21:394-400.
13. Olivieri JJ, Knoll MB, Arn PH. Education format and resource p among registrants of a pediatric-focused CME website. Med Teach 2009;31:e333-e337.
14. Ball DE, Tisocki K, Herxheimer A. Advertising and disclosure of funding on patient organisation websites: A crosssectional survey. BMC Public Health 2006;6:201.
15. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. N Engl J Med 2007;356:1742-1750.
16. Anhang R, Wright TC Jr., Smock L, Goldie SJ. Women's desired information about human papillomavirus. Cancer 2004;100:315-320.
17. Cox JT. The clinician's view: Role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors. Arch Pathol Lab Med 2003;127:950-958.
18. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-362. (Pubitemid 35446606)
19. Cicchetti DV. The precision of reliability and validity estimates re-visited: Distinguishing between clinical and statistical significance of sample size requirements. J Clin Exp Neuropsychol 2001;23:695-700.
20. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103: 619-631.
21. Rebolj M, Bais AG, van BM, et al. Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies. Int J Cancer 2007;121:1529-1535.
22. Rothman SM, Rothman DJ. Marketing HPV vaccine: Implications for adolescent health and medical professionalism. JAMA 2009;302:781-786.
23. Spingarn RW, Berlin JA, Strom BL. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Acad Med 1996;71:86-88.
24. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000;283:373-380. (Pubitemid 30051756)
25. Irwin K, Montano D, Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol 2006;108: 397-409.
26. Roland K, Saraiya M, Benard V. HPV co-testing in the United States and impact on screening intervals. Poster presented at: International Papillomavirus Conference, May 5-14, 2009; Malmö, Sweden. Abstract P-04.11.
27. Saraiya M, Irwin KL, Carlin L, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer 2007;110:1024-1032.
28. Jhala D, Eltoum I. Barriers to adoption of recent technology in cervical screening. Cytojournal 2007;4:16.
29. Fordis M, King JE, Ballantyne CM, et al. Comparison of the instructional efficacy of Internet-based CME with live interactiveCMEworkshops: Arandomized controlled trial.JAMA 2005;294:1043-1051.
30. Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: A review of systematic reviews. Int J Technol Assess Health Care 2005;21:380-385.